Search research articles
Contact Us
Filters
Showing results (11-20 of 59) with videos related to
Page
of 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
December 10, 1997
A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer
P Kirkbride, K Gelmon, E Eisenhauer, et al.
Anticancer Research
|
May 1, 1995
Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative
G De Jong, K Gelmon, M Bally, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 1993
A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group
R W Gregg, L Kaizer, S Fine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2012
Targeting triple-negative breast cancer: optimising therapeutic outcomes
K Gelmon, R Dent, J R Mackey, et al.
Anti-Cancer Drug Design
|
July 20, 2000
In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines
S A Johnstone, K Gelmon, L D Mayer, et al.
Journal of the National Cancer Institute
|
February 16, 1994
Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group
A Arnold, J Ayoub, L Douglas, et al.
Current Oncology (Toronto, Ont.)
|
June 20, 2015
Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience
E Baxter, L Gondara, C Lohrisch, et al.
Investigational New Drugs
|
May 4, 2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
K Gelmon, H Hirte, B Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1998
Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study
F A Shepherd, R Beaulieu, K Gelmon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2004
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers
M J MacKenzie, H W Hirte, L L Siu, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 59) with videos related to
Sort By:
Page
of 6
International Journal of Radiation Oncology, Biology, Physics
|
December 10, 1997
A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer
P Kirkbride, K Gelmon, E Eisenhauer, et al.
Anticancer Research
|
May 1, 1995
Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative
G De Jong, K Gelmon, M Bally, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 1, 1993
A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group
R W Gregg, L Kaizer, S Fine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 21, 2012
Targeting triple-negative breast cancer: optimising therapeutic outcomes
K Gelmon, R Dent, J R Mackey, et al.
Anti-Cancer Drug Design
|
July 20, 2000
In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines
S A Johnstone, K Gelmon, L D Mayer, et al.
Journal of the National Cancer Institute
|
February 16, 1994
Phase II trial of 13-cis-retinoic acid plus interferon alpha in non-small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group
A Arnold, J Ayoub, L Douglas, et al.
Current Oncology (Toronto, Ont.)
|
June 20, 2015
Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience
E Baxter, L Gondara, C Lohrisch, et al.
Investigational New Drugs
|
May 4, 2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
K Gelmon, H Hirte, B Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 1998
Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study
F A Shepherd, R Beaulieu, K Gelmon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2004
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers
M J MacKenzie, H W Hirte, L L Siu, et al.
Page
of 6